12:00 , Aug 22, 2019 |  BC Extra  |  Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
21:42 , Jul 3, 2019 |  BC Extra  |  Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing...
06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Calliditas raises over $70M in Swedish IPO

Renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK650 million ($73.4 million) on June 15 through the sale of 14 million shares at SEK45 in an IPO on NASDAQ Stockholm. The company expects to begin...
23:04 , Aug 15, 2017 |  BC Extra  |  Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

Neurology play Cerecor Inc. (NASDAQ:CERC) said Uli Hacksell retired as president and CEO. CBO John Kaiser will be interim CEO while the company searches for a permanent replacement. Antibody play Allakos Inc. (San Carlos, Calif.)...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Pharmalink completes venture financing

Pharmalink AB , Stockholm, Sweden   Business: Renal, Transplant   Date completed: 2015-10-01   Type: Venture financing   Raised: SEK100 million ($11.9 million)   Investors: Investinor A/S; Industrifonden ; existing investors  ...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Company News

Synartro, Pharmalink deal

Pharmalink purchased an undisclosed product from Synartro that is comprised of an anti-inflammatory drug conjugated to a biopolymer and was created using Synarto’s drug delivery technology. Pharmalink plans to develop the product to treat osteoarthritis....
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Nefecon: Phase IIb data

The double-blind, European Phase IIb NEFIGAN trial in more than 150 patients with primary IgA nephropathy at risk of developing end-stage renal disease (ESRD) was stopped early after a planned interim analysis by a DSMB...
02:18 , Apr 15, 2015 |  BC Extra  |  Clinical News

Pharmalink's Nefecon meets nephropathy endpoint

Pharmalink AB (Stockholm, Sweden) stopped the Phase IIb NEFIGAN trial early after an interim analysis showed Nefecon ( PL-56 ) met the primary endpoint to treat IgA nephropathy. Daily administration of Nefecon led to statistically...